Assessment of platelet function in patients with stroke using multiple electrode platelet aggregometry: a prospective observational study

Ahmed Sabra¹,²,³†, Sophia N. Stanford¹,²,³†, Sharon Storton², Matthew Lawrence¹,², Lindsay D'Silva¹,², Roger H. K. Morris⁴, Vanessa Evans², Mushtaq Wani⁵, John F. Potter⁵ and Phillip A. Evans¹,²,⁷*

Abstract

Background: There is a link between high on-treatment platelet reactivity (HPR) and adverse vascular events in stroke. This study aimed to compare multiple electrode platelet aggregometry (MEA), in healthy subjects and ischaemic stroke patients, and between patients naive to antiplatelet drugs (AP) and those on regular low dose AP. We also aimed to determine prevalence of HPR at baseline and at 3–5 days after loading doses of aspirin.

Methods: Patients with first ever ischaemic stroke were age and sex-matched to a healthy control group. Three venous blood samples were collected: on admission before any treatment given (baseline); at 24 h and 3–5 days after standard treatment. MEA was determined using a Multiplate® analyser and agonists tested were arachidonic acid (ASPI), adenosine diphosphate (ADP) and collagen (COL).

Results: Seventy patients (mean age 73 years [SD 13]; 42 men, 28 women) were age and sex-matched to 72 healthy subjects. Thirty-three patients were on antiplatelet drugs (AP) prior to stroke onset and 37 were AP-naive. MEA results for all agonists were significantly increased in AP-naive patients compared to healthy subjects: ADP 98 ± 31 vs 81 ± 24, p < 0.005; ASPI 117 ± 31 vs 98 ± 27, p < 0.005; COL 100 ± 25 vs 82 ± 20, p < 0.005. For patients on long term AP, 33% (10/30) of patients were considered aspirin-resistant. At 3–5 days following loading doses of aspirin, only 11.1% were aspirin resistant based on an ASPI cut-off value of 40 AU*min.

Conclusions: Many patients receiving low dose aspirin met the criteria of aspirin resistance but this was much lower at 3–5 days following loading doses of aspirin. Future studies are needed to establish the causes of HPR and potential benefits of individualizing AP treatment based on platelet function testing.

Keywords: Ischaemic stroke, Multiple electrode platelet aggregometry, Platelet function, Antiplatelet therapy, Aspirin, Clopidogrel, Aspirin resistance

Background

Platelets play a major role in arterial thrombus formation and therefore in the pathophysiology of ischaemic stroke [1–4]. Excessive platelet activation leads to increased thrombin generation and potentially abnormal thrombus formation [5]. Hence the importance of oral antiplatelet drugs, which are the mainstream therapy in the primary and secondary prevention of cerebrovascular disease [6, 7]. Currently, the antiplatelet (AP) drugs most widely used are aspirin and clopidogrel, and multiple electrode platelet aggregometry (MEA) has been used to study their effects on platelet function [8–11]. MEA has also been used to investigate the effects of non-opioid analgesics [12], anticoagulants [13], antifibrinolytics [14] and temperature [15] on platelet aggregation.
Despite the effectiveness of aspirin in the primary and secondary prevention of atherothrombotic disease, patients continue to suffer recurrent thromboembolic vascular events whilst on AP treatment [16]. This recurrence has been associated with high on-treatment platelet reactivity (HPR), with up to more than 60% of subjects being reported to be resistant to antiplatelet therapy (aspirin or clopidogrel) [17, 18]. Although some studies showed a link between HPR and major adverse vascular events [19, 20], the use of platelet function analysis to detect and manage HPR continues to be debated. Most studies that investigated HPR were undertaken for patients already receiving antiplatelet therapy without assessing baseline platelet reactivity [19, 20], which may partly explain the conflicting results. We were therefore interested in whether patients have a higher platelet reactivity at baseline, which may contribute to the suboptimal response to treatment. Hence this study aimed to compare platelet function, as determined by MEA, in healthy subjects and stroke patients prior to treatment initiation and between patients naïve to AP therapy and those on regular low dose aspirin or clopidogrel.

Methods
Study design
A prospective observational study to compare platelet function between age matched healthy controls and patients with ischaemic stroke using MEA; and between patients naïve to and on baseline AP therapy.

Patient population
First time ischaemic stroke patients were recruited upon their presentation to the Emergency Department of a large teaching hospital (ABMU Health Board, Swansea, UK). Once a provisional diagnosis of stroke was made by the care team, strict inclusion criteria were applied. The inclusion criteria including only adults (≥18 years), the clinical assessment of ischaemic stroke was based on clinical history, examination and neuroradiology, the diagnosis of stroke was further validated by a member of the research team using WHO diagnostic criteria [21]. Full informed consent was sought from the outset and for those unable to consent due to lack of mental capacity assent was sought from personal or professional legal representatives. Exclusion criteria included: previous stroke; recieving anticoagulant therapy; use of nonsteroidal anti-inflammatory drugs (NSAIDs) aside from low-dose aspirin; suffering from a disease known to alter coagulation (e.g. liver disease, malignancy, renal failure) or imminent death. Investigators were blinded to the result of MEA testing. Stroke patients were compared to an age-matched control group recruited from a healthy local population who were subsequently tested at the Haemostasis Biomedical Research Unit (HBRU). The helathy volunteers were recruited via various advertising means including posters, internal email or direct invitations of staff and patients’ relatives. Healthy volunteers were recruited if over 18 years of age without any significant co-morbidities aside from mild conditions not likely to affect platelet function (e.g. mild asthma or dyspepsia) and they were excluded if they had taken any NSAIDs or other agents that could affect platelet activity in the 2 weeks prior to testing.

Blood sampling and data collection
One venous blood sample was collected from stroke patients on admission before any treatment given (baseline). Blood samples were also collected at 24 h and 3–5 days after standard treatment (aspirin 300 mg daily, or thrombolysis followed by aspirin 300 mg after the 24-h imaging to rule out intracerebral bleeding). The first 2 mL blood was discarded. Blood was then collected in 3 mL tubes containing 25 μg/mL hirudin (Dynabyte, Munich, Germany) as per the manufacturer’s recommendations. Further blood samples were taken for Full Blood Count (FBC), Prothrombin Time (PT), activated partial thromboplastin time (APTT) and fibrinogen levels. FBC samples were analysed on a Sysmex CA 2100 (TOA Medical Electronics) automated haematology analyser and routine clotting testing was undertaken using Sysmex CA1500 analyser. Fibrinogen concentrations were measured by ‘claus’ method. The analysers were calibrated according to manufacturer’s instructions and fibrinogen calibration was checked against the second International Fibrinogen Standard Version 4 (NIBSC code 96/612). All reagents were obtained from Dade Behring.

Multiple electrode aggregometry
Multiple electrode aggregometry (MEA) is a method that tests platelet function in whole blood, based on whole blood impedance aggregometry. In this study the Multiplate® analyser (Dynabyte GmbH, Munich, Germany) was used. The Multiplate® has five testing areas which can be loaded with the MEA test cells, each of the test cells has two independent sensor units which are made of two silver-coated, highly conductive copper wires. The Multiplate works by measuring platelet adhesion and aggregation to these conductive wires following activation of the platelets. As aggregation increases there is an increase in electrical impedance between the wires which is recorded on the Multiplate® device [22]. Platelet aggregation determined by MEA is calculated from the Area under the Curve (AUC) which is taken from the measured electrical impedance and quantified by arbitrary aggregation units over time (AU*min) (Fig. 1).

Hirudinated whole blood was kept at room temperature for 30 min before testing platelet aggregation using the Multiplate® analyser. A volume of 300 μl hirudinated
blood was added to 300 μl of saline at 37 °C and allowed to incubate for 3 min in individual test cells. Then the following specific agonists were added to respective test cells and electrical impedance measured:

- Adenosine diphosphate (ADP, 20 μl of 0.2 mM stock solution) which triggers platelet activation via platelet ADP receptors (i.e. P2Y12 receptor that is inhibited by clopidogrel).
- ASPI test reagent (20 μl of 15 mM stock solution) contains arachidonic acid. This triggers platelet aggregation via platelet cyclooxygenase, which is blocked by aspirin.
- Collagen (20 μl of 100 μg/ml stock solution) which activates platelets via the collagen receptor.

HPR has been defined based on the manufacturer’s recommendations and published data with cut-offs of 50 AU*min for ADP-induced [19, 23] and 40 AU*min for ASPI-induced aggregation [24].

**Statistical analysis**
To establish the baseline characteristics of the healthy and stroke groups descriptive analyses were performed. All the data was assessed for normality using normal probability plots and Shapiro–Wilk test of normality. Percentages are used to summarize categorical variables and chi-square tests were used to assess any difference between the groups. Continuous variables are presented as mean and standard deviation (SD) unless otherwise stated. Differences were assumed to be significant at 5% level. Two-sample Student's t-test were used to compare differences between different groups. Any differences were then evaluated by using analysis of covariance (ANCOVA) whilst controlling for the effect of smoking. IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp. Released 2013, Armonk, NY) was used to perform the analysis.

**Results**
One hundred twenty two patients with suspected first-ever ischaemic stroke were recruited between May 2012 and February 2014. 52 patients were excluded. The reason for exclusion included: 18 had stroke mimics such as Bell’s palsy; sepsis and brain tumour; 8 transient ischemic attacks (TIA); 8 had a haemorrhagic stroke; 3 cancers; 1 renal failure; 6 found to have been given loading aspirin prior to blood collection and 4 were taking NSAIDs such as Ibuprofen and Diclofenac. Leaving seventy patients (42 men and 28 women; mean age, 73.1 ± 13.3 years) with confirmed first time ischaemic stroke, these patients were used in the analysis. Their baseline characteristics are presented in Table 1. Stroke patients were matched for sex and age with 72 healthy subjects (mean age, 71.3 ± 6.9 years, \( p = 0.29 \); 40 men and 32 women, 0.59) recruited from the same population as the stroke patients. Whilst matched for age and sex the stroke group did have a significantly higher proportion of current smokers than healthy controls (22.9% versus 6.9%, \( p = 0.01 \)).

Full blood count and coagulation profile results are presented in Table 2 for all groups. Of the 70 patients, 31 were thrombolysed and 39 were loaded with 300 mg aspirin. At baseline 33 stroke patients were on antiplatelet therapy (26 on 75 mg of aspirin only, 3 on 75 mg of clopidogrel only and 4 on both agents) and 37 were AP-naive. Multiplate® analysis showed that ASPI was the only significant parameter that differed between the healthy subjects and the entire stroke group (97.6 ± 27.3 versus 81.1 ± 50.1, \( p = 0.02 \)). These differences reversed when healthy subjects were only compared with AP-naive patients (97.6 ± 27.3 versus 117.4 ± 30.7, \( p < 0.005 \)).
the AP-naive patients, significantly higher values were also observed for ADP and Collagen as shown in Table 3. All MEA parameters were significantly lower in patients who were on regular antiplatelet therapy at baseline as compared to healthy subjects and AP-naive patients (Table 3). All these differences continued to be significant after controlling for smoking status using ANCOVA.

### Table 1 Baseline characteristics of patients with stroke (n=70)

| Group | Healthy (n 72) | Stroke (n 70) |
|-------|---------------|--------------|
| Age, mean ± SD | 73.1 ± 13.3 | 74.7 ± 13.5 |
| Sex: male/female | 42/28 | 41/29 |
| Current Smoker | 16 (22.9%) | 20 (28.6%) |
| Hypertension | 48 (68.6%) | 55 (78.6%) |
| Ischaemic heart disease | 21 (30%) | 25 (35.7%) |
| Atrial fibrillation | 18 (25.7%) | 22 (31.4%) |
| Diabetes mellitus | 14 (20%) | 15 (21.4%) |
| Previous TIA | 11 (15.7%) | 14 (20%) |
| Hyperlipidaemia | 27 (38.6%) | 30 (42.9%) |
| Antiplatelets | | |
| Aspirin only | 26 | 27 |
| Clopidogrel only | 3 | 4 |
| Both drugs | 4 | 5 |
| Statins | 26 (37.1%) | 30 (42.9%) |
| Glucose (mmol/L) | 6.5 ± 1.7 | 6.6 ± 1.8 |
| Creatinine (μmol/L) | 97 ± 27.2 | 98 ± 30.1 |
| D-dimer (ng/mL) | 208 (104–488) | 230 (120–500) |
| C-reactive protein (mg/L) | 4 (1–10) | 5 (2–15) |

| TOAST classification: | |
| Large artery | 20 | |
| Cardio-embolic | 14 | |
| Small vessel (lacunar) | 29 | |
| Undetermined aetiology | 7 | |

Values are presented as percentages, mean ± SD or median (interquartile range)

### Table 2 Haematological tests for stroke patients and healthy subjects

| Group | Healthy (n 72) | Stroke (n 70) |
|-------|---------------|--------------|
| Platelets (x10^3/μl) | 245 ± 50 | 256 ± 79 | 273 ± 83 | 238 ± 71 |
| Hb (g/dl) | 14.3 ± 1.3 | 14.2 ± 1.7 | 14.4 ± 1.6 | 13.9 ± 2 |
| HCT (g/l) | 0.43 ± 0.04 | 0.42 ± 0.04 | 0.42 ± 0.04 | 0.41 ± 0.05 |
| PT (secs) | 10.6 ± 0.7 | 10.6 ± 0.6 | 10.5 ± 0.5 | 10.8 ± 0.7* |
| APTT (secs) | 26 ± 2.3 | 24.2 ± 2.2* | 23.9 ± 2* | 24.4 ± 2.3* |
| FBG (g/l) | 3.2 ± 0.5 | 3.8 ± 0.8* | 3.9 ± 0.9* | 3.7 ± 0.7* |

Values reported as mean and standard deviation, AP antiplatelet naive at baseline

*p < 0.05 compared with healthy controls
†p < 0.05 compared with AP-naive group
‡p < 0.0000005 compared with healthy controls
***p < 0.0005 compared with AP-naive group
****p < 0.05 compared with AP-naive group

### Table 3 Results of MEA for stroke patients and healthy subjects

| Group | Healthy (n 72) | Stroke (n 70) |
|-------|---------------|--------------|
| ADP | 81.3 ± 24.3 | 89.8 ± 30.1 | 98.2 ± 31.1** | 80.3 ± 26.4† |
| ASPI | 97.6 ± 27.3 | 81.1 ± 50.1* | 117.4 ± 30.7*** | 40.4 ± 33.2**† |
| Collagen | 82.4 ± 20.2 | 82.8 ± 29.1 | 99.5 ± 25** | 64.1 ± 20.9***† |

Values reported as mean and standard deviation, AP antiplatelet naive at baseline

*p < 0.05 compared with healthy controls
**p < 0.005 compared with healthy controls
***p < 0.0005 compared with healthy controls
†p < 0.05 compared with AP-naive group
‡p < 0.0000005 compared with AP-naive group

### Prevalence of high on-treatment platelet reactivity (HPR)

Based on the cut off values for HPR, 10 patients (33%) on long term aspirin (baseline sample) were aspirin-resistant or low responders but only 4 had ASPI values > 60 AU*min. Of the seven patients on clopidogrel at baseline, 5 (71%) were aspirin-resistant (4 patients had ADP values above 85 AU*min).

ASP results were available for 36 patients at 3–5 days after 300 mg loading doses of aspirin. 13.6% (3/22) aspirin naive patients and 7.1% (1/14) on long term aspirin were considered aspirin-resistant but only one patient (1/36) had ASPI values > 60 AU*min. At 24 h, it is understandable that for thrombolysis patients (dotted lines, Fig. 2) ASPI values were higher than aspirin group (solid lines) because they have not received any aspirin pending the 24 h head CT scan to rule out intracerebral haemorrhage. The results of serial ASPI testing at baseline, 24 h and 3–5 days for patients who were aspirin-naive or on long term aspirin are shown in Fig. 2.

### Discussion

Our study is the first to assess platelet reactivity using MEA in patients with stroke at baseline before loading doses of 300 mg aspirin were given. The main finding showed that platelet aggregation in AP-naive patients is higher than in healthy subjects for all pathways investigated. However, it is difficult to ascertain if this is due to an underlying high platelet reactivity or is secondary to the acute event. Future larger studies are needed to confirm our findings and investigate this assumption.

Secondly, our study detected changes between long-term aspirin users and aspirin-naive patients. Despite the proved effectiveness of AP therapy, patients continue to have recurrent vascular events while on treatment [16]. In agreement with previously reported studies [25], about 50% of patients in our study were taking one or more AP drugs at presentation but this did not prevent stroke. New approaches to improve clinical outcomes used MEA to individualise antiplatelet therapy [19] and hence highlighting the importance of our findings. Based on definition of aspirin resistance in previous studies,
33.3% of patients would be defined as aspirin-resistant according to ASPI results. As more than 60% of long term aspirin users are considered responders, the use of loading dose of aspirin in these patients may not have any additional benefit. It may indicate the need to investigate thoroughly for underlying silent risk factors such as paroxysmal atrial fibrillation. The emergence of new P2Y12 antagonists and ongoing uncertainties of platelet function testing dictate the need for larger RCT to answer these questions and investigate the clinical benefit of AP switching strategy in stroke patients based on MEA results. This supports the recommendation by the National Institute for Health and Care Excellence for future research in this area about effectiveness and safety of clopidogrel, alone or in combination with aspirin, in treating stroke and TIA [26].

Thirdly, our study also detected the effect of aspirin loading therapy on platelet aggregation (ASPI) in acute stroke. Interestingly at 3–5 days after in hospital administration of aspirin, only 7.1% were non responders at 3–5 days. Horizontal dotted black lines indicate ASPI cut-off values for aspirin resistance, as reported in the literature.
recognise and act on stroke symptoms, little has been done to improve compliance. Previous studies suggested female sex, single marital status, lower education level, depression, diabetes mellitus, polypharmacy, and smoking as predictors of poor compliance [27]. Hence, more educational initiatives targeting these high-risk patients of poor compliance should be done to enforce the importance of taking AP regularly. Another possible explanation of this discrepancy is the timing of baseline sample after aspirin intake, which was variable, whereas it was 2–4 h after administering aspirin for subsequent samples. Timing of platelet function testing has been acknowledged as a factor explaining the variability in the results with serum salicylate level peaking at 1 h after administration [5, 29]. The higher aspirin dose given acutely in hospital is another potential factor but published data do not support this assumption reporting that doses between 30 and 1300 mg per day have the same clinical efficacy [18, 30]. Nonetheless some may argue that this does not equate to similar platelet inhibition as detected by platelet function tests. Despite the availability of a wide-range of techniques to investigate platelet function, their reliability has been questioned. A previous study showed poor correlation between six platelet function tests to define aspirin-resistance [31], and this variation in methodology may be a factor in explaining the difficulties in determining the true prevalence of AP resistance. Hence it is important to link these tests to clinical endpoints to establish cut-offs of each assay. Although LTA may be considered the gold standard for the determination of platelet activity, we chose to use Multiplate® in this study because it is a standardized fully automated point-of-care test that is relatively easy to use without many of the technical limitations of the previous assays [32]. Additionally the feasibility of using Multiplate® in the context of routine hospital service has been ascertained to provide reproducible and precise results in stroke patients [33]. This potentially makes our findings easier to replicate and translate into large clinical studies to investigate clinical endpoints.

Limitations: this is a small single centre study and hence may not be generalizable to other populations. Aspirin and clopidogrel intake at baseline was self-reported by patients or their family. Although MEA results indicate two thirds of the patients were taking aspirin, confirming compliance is an important issue but was beyond the scope of this study. Another limitation is the higher number of active smokers in the stroke group as compared to healthy subjects. Conflicting results exist about the effect of smoking on platelet function testing [20, 24, 34]. However in our study, ANCOVA analysis was used to control for the effect of smoking. Another limitation is the attrition rate despite the prospective study design. Multiplate analysis at 3–5 days was not possible for all cases for various reasons (patient discharged or transferred to another hospital, death, declined further samples, difficult to bleed). Despite the strict inclusion and exclusion criteria heterogeneity of stroke presentations and patient populations are key issues to consider when investigating stroke as noticed in this study, and subgroup analysis should be interpreted with caution.

Conclusions
Despite these limitations our study reports a higher platelet reactivity as determined by Multiplate® in AP-naive stroke patients for all pathways as compared to healthy subjects. Many patients receiving low dose aspirin met the criteria of HPR or drug resistance but the prevalence was much lower at 3–5 days of inpatient treatment. It also reiterates the importance of compliance and probably timing of testing as potential factors affecting MEA testing. It also questions the benefits of giving aspirin in patients with laboratory evidence of response when this did not prevent recurrent stroke. Hence further work in large prospective multicentre trials is needed to confirm that the laboratory results can be translated onto clinical endpoints. For any future research the main question is whether the use of MEA to individualise AP treatment in stroke/TIA results in better clinical outcomes. We recommend establishing platelet reactivity at baseline to determine best AP therapy and then monitor their effect at 3 days to decide whether a switch is warranted. This may also help establish the true causes of HPR in stroke and the value of MEA in predicting future events.

Abbreviations
ADP: Adenosine diphosphate; ANCOVA: Analysis of covariance; AP: Antiplatelet drugs; ASP: Arachidonic acid; AU*min: Aggregation units over time; AUC: Area under the curve; COL: Collagen; HPR: High on-treatment platelet reactivity; LTA: Light transmission aggregometry; MEA: Multiple electrode platelet aggregometry; NSAIDs: Nonsteroidal anti-inflammatory drugs; RCT: Randomised control trial; SD: Standard deviation; TIA: Transient ischaemic attack

Acknowledgments
Our thanks go to the staff in the Emergency and Stroke Department and the research team in NISCHR Haemostasis Biomedical Research Unit at Morriston Hospital for their support.

Funding
This study was funded by the National Institute for Social Care and Clinical Health Research (NISCHR).

Availability of data and materials
The datasets generated and/or analyzed during this study are not publicly available because they contain protected health information but de-identified data are available from the corresponding author on reasonable request.
Authors’ contributions
PAE conceived the study. AS, SNS, ML and PAE designed and coordinated the study. AS, SNS and PAE drafted the article and interpreted the data. AS, SNS, SS and LD recruited the patients and collected blood sample. AS, SNS, ML and LD performed the rheology tests. ML provided rheological advice. SS and VE collected the patient data. AS and RHOM performed the statistical analyses and interpreted the data. MW and JFP revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study has been approved by the local ethics committee (South West Wales Research Ethics Committee). Written informed consent has been obtained for all patients.

Received: 15 August 2016 Accepted: 5 December 2016
Published online: 09 December 2016

References
1. Fisher M, Levine PH, Fullerton AL, Forsberg A, Duffy CP, Hoogasian JJ, Drachman DA. Marker proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol. 1982;39:692–5.
2. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol. 1990;47:1075–9.
3. Joseph R, D’andrea G, Oster SB, Welch KM. Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents. Stroke. 1989;20:38–44.
4. Tohgi H, Suzuki H, Tamura K, Kimura B. Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. Stroke. 1991;22:17–21.
5. Majilovic MV, Shulga O, Bloch S, Covicliuc-Sternic N, Alekic V, Bornstein NM. Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurol Scand. 2013;128:213–9.
6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1609–16.
7. Cossalter G, Kabl M, Marschalek C, Kozek-Langenecker SA. The effects of test temperature and storage temperature on platelet aggregation: a whole blood in vitro study. Anesth Analg. 2006;102:1280–4.
8. Antithrombotic Triallists, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.
9. Lim ST, Coughan CA, Murphy SJ, Fernandez-Cadenas I, Montaner J, Thijss V, Marquardt L, McCabe DHJ. Platelet function testing in transient ischaemic attack and ischaemic stroke: a comprehensive systematic review of the literature. Platelets. 2015;26(5):402–12.
10. Sztirma UK, Sai K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci. 2005;232(2–3):163–9.
11. Christ G, Siller-Matula JM, Francesconi M, Dechent C, Grohs K, Podzyczek-Schweighofer A. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open. 2014;4:10.
12. Feher A, Pusgh C, Harang G, Gasztonyi B, Papp E, Werling D, Menyhart M, Komaromy H, Szapary L, Feher G. Aspirin resistance in cerebrovascular patients. Int J Cardiol. 2011;152(1):111–2.
13. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54:541–53.
14. Toh C, Calatzis A, Perez S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–8.
15. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2005;45:1193–1200.
16. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:945–96.
17. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54:541–53.
18. Christ G, Siller-Matula JM, Francesconi M, Dechent C, Grohs K, Podzyczek-Schweighofer A. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open. 2014;4:10.
19. Feher A, Pusgh C, Harang G, Gasztonyi B, Papp E, Werling D, Menyhart M, Komaromy H, Szapary L, Feher G. Aspirin resistance in cerebrovascular patients. Int J Cardiol. 2011;152(1):111–2.
20. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54:541–53.
21. Toh C, Calatzis A, Perez S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–8.
22. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2005;45:1193–1200.
23. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:945–96.
24. Al-Azzam SI, Alzoubi KH, Khabor O, Alowidi A, Tawalbeh D. The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta Cardiol. 2012;67:445–8.
25. White JR, Bettencourt-Silva JH, Potter JF, Loke YK, Myint PK. Changes in platelet function assays. PFA-100 and multiplate. Hamostaseologie. 2009;29:1504–9.
26. Mengistu AM, Rohm KD, Boldt J, Mayer J, Suttner SW, Piper SN. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery. Anesth Analg. 2008;107:391–7.
27. Schatbert G, Kabl M, Marschalek C, Kozek-Langenecker SA. The effects of test temperature and storage temperature on platelet aggregation: a whole blood in vitro study. Anesth Analg. 2006;102:1280–4.
28. Antithrombotic Triallists, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1609–60.
29. Feher A, Pusgh C, Harang G, Gasztonyi B, Papp E, Werling D, Menyhart M, Komaromy H, Szapary L, Feher G. Aspirin resistance in cerebrovascular patients. Int J Cardiol. 2011;152(1):111–2.
30. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54:541–53.
31. Toh C, Calatzis A, Perez S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–8.
31. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702–8.
32. Choi JL, Li S, Han JY. Platelet function tests: a review of progresses in clinical application. BioMed Res Int. 2014; Article ID 456569. doi:10.1155/2014/456569
33. Mannu GS, Macartney A, Lambert JR, Bettencourt-Silva JH, Lawn M, Lyall H, Metcalf AK, Potter JF, Wood J, Clark A. The clinical utility of Multiplate analyser measurement in platelet function testing following stroke and transient ischaemic attack. Eur J Haematol. 2015;94:138–44.
34. Al-Azzam SI, Alzoubi KH, Khabour OF, Nusair MB, Al-Hadidi H, Awidi A, Saleh A. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: Environmental and genetic approach. Int J Clin Pharmaco Therap. 2013;51:179–86.